The use of orlistat could be associated with kidney stones in patients with chronic kidney disease
Tirzepatide was developed as a unimolecular dual agonist and moved through the SURPASS (type 2 diabetes) and SURMOUNT (obesity) Phase 3 programs to approval, becoming the first approved GLP-1/GIP dual agonist
Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF (2000) Osteoarthritis: new insights
Understanding the financial commitment upfront helps with planning and prevents interrupted protocols due to budget constraints
The effects of coenzyme Q10 supplementation on biomarkers of exercise-induced muscle damage, physical performance, and oxidative stress: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials